Forward to: IP & Legal

Patent & IP
Intelligence Workflows

Ten agent workflows for IP and Legal -- patent cliff monitoring, Paragraph IV challenge tracking, biosimilar entry intelligence, IP portfolio analysis, patent litigation monitoring, Orange Book assessment, exclusivity tracking, trade secret and data protection analysis, patent strategy benchmarking, and IP intelligence dashboard -- enabling proactive intellectual property strategy powered by comprehensive domain intelligence.

These workflows display realistic demo data for demonstration. In production, the agents connect to your real pharmaceutical data via MCP services or CSV import.
Deployment Options
The entire platform is available as a self-hosted solution or managed service
Self-Hosted
RECOMMENDED FOR ENTERPRISE
Deploy the entire platform on your own infrastructure. Your data never leaves your environment. Bring your own LLM API key (OpenAI, Claude, Gemini) or use local LLMs. Full source code delivered.
Complete source code (Python agents, PHP dashboards, MCP services)
Data stays on your servers — no external data transfer
MCP connectors for clinical trial, regulatory, and research databases
Custom integration and onboarding support available
$999
2 AI Agents
5 integration hrs
$1,999
5 AI Agents
10 integration hrs
$3,999
10 AI Agents
20 integration hrs
one-time license + (optional) $999/yr updates
Managed Platform
FOR AGENCIES & TEAMS
We host and operate the platform for you. Upload data or connect your platforms via secure MCP services or using API. No infrastructure management needed.
Fully managed — no DevOps required on your side
Secure data upload or API-based MCP integration
Dashboard access with your own branded login
Automatic updates and new agent releases
$999/mo
2 AI Agents
5 integration hrs
$1,999/mo
5 AI Agents
10 integration hrs
$3,999/mo
10 AI Agents
20 integration hrs
includes hosting, updates & support
* price may be higher in cases of very high AI processing volumes/demands
Both options include MCP services with connectors for clinical trial, regulatory, and research databases. Data dictionaries define the schema contract between each agent and your data sources.
See example of production dashboards: Programmatic Trading AI Agent Dashboards →

1Patent Cliff Monitoring

AI agent tracks patent expiration timelines, generic entry signals, and revenue at risk from investor presentations and competitor patent strategy disclosures across major branded pharmaceuticals.

1
Track Patent Expiration Impact
/investors/press/legalOpenPageRank
PATENT CLIFF INTELLIGENCE — 2025-2030 ════════════════════════════════════════════════════════ HIGHEST-VALUE PATENT EXPIRATIONS: merck.com: Keytruda (pembrolizumab) Patent expiry: 2028 (base), 2036 (extended litigation) Revenue at risk: $26B annually /investors: "SC formulation and combo strategy to extend franchise" SIGNAL: Largest single-product patent cliff in history abbvie.com: Humira (adalimumab) Patent expiry: US biosimilars now competing (2023+) Revenue erosion: $14B → $5.8B (-59% since LOE) /investors: Skyrizi + Rinvoq replacing — "Humira-free by 2027" SIGNAL: Biosimilar erosion faster than modeled bms.com: Eliquis (apixaban) Patent expiry: 2026 (litigation ongoing) Revenue at risk: $12B annually /legal: Settlement signals emerging with generic filers UPCOMING CLIFFS (revenue at risk): 2026: $38B | 2027: $42B | 2028: $65B (Keytruda) TOTAL 5-YEAR CLIFF: $180B revenue at risk industry-wide

2Paragraph IV Challenge Tracking

AI agent monitors Paragraph IV certification filings, ANDA approvals, and litigation outcomes that signal generic entry timelines for branded pharmaceutical products.

1
Track Generic Challenge Activity
/press/legal/investorsOpenPageRank
PARAGRAPH IV CHALLENGE INTELLIGENCE ════════════════════════════════════════════════════════ ACTIVE CHALLENGES — HIGH VALUE: Eliquis (BMS/Pfizer): 8 ANDA filers tevausa.com: First-filer status — 180-day exclusivity bms.com: /legal — "Settlement negotiations ongoing" SIGNAL: Settlement likely H2 2026 — generic entry 2027-2028 Jardiance (Boehringer/Lilly): 4 ANDA filers boehringer-ingelheim.com: /legal — litigation active SIGNAL: Composition patent strong — generic entry 2029 likely Ozempic (Novo Nordisk): 3 ANDA filers novonordisk.com: /legal — "Will vigorously defend" SIGNAL: Device patents provide additional protection to 2032 GENERIC APPROVAL TRENDS: ANDA approvals YTD: 142 First-to-file exclusivity grants: 18 Average time from Para IV filing to approval: 4.2 years TREND: Generic challenge activity at 5-year high — small molecule pressure

3Biosimilar Entry Intelligence

AI agent tracks biosimilar development programs, regulatory submissions, interchangeability designations, and market entry strategies from biosimilar developer domains.

1
Monitor Biosimilar Pipeline
/products/press/investorsOpenPageRank
BIOSIMILAR ENTRY INTELLIGENCE ════════════════════════════════════════════════════════ ACTIVE BIOSIMILAR MARKETS: Adalimumab (Humira) — 11 biosimilars approved in US sandoz.com: Hyrimoz — Interchangeable designation biocon.com: Yusimry — Low-cost entry strategy Market erosion: 55% reference product share lost Bevacizumab (Avastin) — 7 biosimilars competing Average discount: -42% vs reference product UPCOMING BIOSIMILAR ENTRIES: Stelara (ustekinumab) — LOE 2025 — 8 biosimilars filed jnj.com: /investors — "Stelara biosimilar impact modeled at $5B" SIGNAL: Highest-value biosimilar entry ever — 8 competitors Keytruda (pembrolizumab) — 2028+ timeline samsung-biologics.com: Biosimilar in Phase III SIGNAL: First PD-1 biosimilar — unprecedented complexity INTERCHANGEABILITY TREND: Interchangeable designations granted: 6 (growing rapidly) SIGNAL: Interchangeability enabling pharmacy substitution — faster erosion

4IP Portfolio Competitive Analysis

AI agent analyzes competitor IP portfolios by monitoring patent filing activity, prosecution strategies, and portfolio composition signals from legal and investor page disclosures.

1
Analyze IP Portfolios
/investors/legal/productsOpenPageRank
IP PORTFOLIO COMPETITIVE ANALYSIS ════════════════════════════════════════════════════════ PORTFOLIO STRENGTH RANKING: roche.com: 2,847 active pharma patents — strongest portfolio Focus: ADCs, bispecifics, diagnostics companion /investors: "IP runway extends to 2035+ for key franchises" pfizer.com: 2,234 active patents Focus: Small molecule, mRNA, gene therapy /investors: Patent estate valued at est. $45B novartis.com: 1,987 active patents Focus: Radioligand therapy, cell therapy SIGNAL: Radioligand IP moat strengthening — 340 patents filed in 2025 IP STRATEGY SIGNALS: Formulation patents: Lifecycle management — 42% of new filings Method of treatment: Expanding — 28% of new filings Platform patents: LNP, ADC linker, degrader scaffolds — high value modernatx.com: /legal — LNP patent litigation with Arbutus SIGNAL: mRNA LNP IP landscape contested — settlement likely

5Patent Litigation Monitoring

AI agent tracks patent infringement lawsuits, Hatch-Waxman litigation, and BPCIA proceedings by monitoring court filings, settlement signals, and legal page updates from involved parties.

1
Track Patent Litigation
/legal/press/investorsOpenPageRank
PATENT LITIGATION INTELLIGENCE ════════════════════════════════════════════════════════ HIGH-VALUE LITIGATION — ACTIVE: Eliquis Patent Defense (BMS/Pfizer v. Multiple) bms.com: /legal — 30-month stay expires Q3 2026 SIGNAL: $12B/yr product — settlement pressure building Keytruda Patent Defense (Merck v. Multiple) merck.com: /investors — "Confident in patent estate" SIGNAL: Complex biologic patent litigation — outcome uncertain mRNA LNP IP (Moderna v. Pfizer/BioNTech) modernatx.com: /legal — Cross-licensing discussed pfizer.com: /legal — Counterclaims filed SIGNAL: Settlement most likely outcome — cross-license expected SETTLEMENT ACTIVITY: Settlements this quarter: 6 — mostly authorized generic deals Average early-entry period: 18 months before patent expiry SIGNAL: Authorized generic settlements becoming standard resolution PTAB / IPR TRENDS: IPR petitions filed: 42 (pharma patents) Institution rate: 68% — high challenge success

6Orange Book & Exclusivity Analysis

AI agent monitors Orange Book listings, exclusivity grants, and patent listing strategies that define competitive entry barriers and generic approval timelines.

1
Analyze Orange Book Strategy
/legal/products/complianceOpenPageRank
ORANGE BOOK & EXCLUSIVITY INTELLIGENCE ════════════════════════════════════════════════════════ PATENT LISTING STRATEGIES: merck.com: Keytruda Orange Book patents: 127 listed (extensive thicket) Latest expiry: 2036 (method of treatment) SIGNAL: Patent thicket strategy — maximum generic delay novonordisk.com: Ozempic/Wegovy Orange Book patents: 48 listed Device patents extending protection to 2032 SIGNAL: Device IP critical for peptide generic defense EXCLUSIVITY EXPIRATIONS: NCE (5-year) expiring 2026: 14 products Pediatric (6-month) extensions granted: 8 this quarter Orphan Drug (7-year) active: 234 products REGULATORY EXCLUSIVITY TRENDS: FDA scrutinizing Orange Book listings — delisting proceedings increasing Biosimilar reference product exclusivity: 12 years (unchanged) SIGNAL: Patent thicket criticism growing — legislative risk for late-listed patents

7Data Exclusivity & Trade Secret Tracking

AI agent monitors regulatory data exclusivity periods, trade secret protection strategies, and know-how advantages that provide competitive barriers beyond patent protection.

1
Track Non-Patent IP Protection
/legal/compliance/productsOpenPageRank
DATA EXCLUSIVITY & TRADE SECRET INTELLIGENCE ════════════════════════════════════════════════════════ DATA EXCLUSIVITY WINDOWS: US NCE (5+3 year): Products entering vulnerable window (year 4-5): 23 NCE products — generic ANDA filing eligible within 12 months EU Data Exclusivity (8+2+1 year): Longer EU protection providing 2-3 year buffer vs US SIGNAL: EU launch-first strategy gaining traction for lifecycle management BIOLOGIC DATA PROTECTION (12-year BPCIA): Biosimilar filing eligible (12 yr expired): Humira, Avastin, Herceptin — all exposed Upcoming: Opdivo (2028), Keytruda (2030) SIGNAL: 12-year clock expiring on first wave of PD-1/PD-L1 TRADE SECRET ADVANTAGES: Manufacturing know-how: regeneron.com: VelociSuite platform — trade secret protected modernatx.com: mRNA manufacturing process IP SIGNAL: Process trade secrets providing competitive moats beyond patents Cell therapy manufacturing: Vein-to-vein process complexity = natural barrier to biosimilar entry

8Lifecycle Management Strategy

AI agent detects lifecycle management activities including reformulation, new dosage forms, authorized generics, and indication expansion strategies designed to extend product revenue beyond patent expiry.

1
Track Lifecycle Extension Strategies
/products/press/investorsOpenPageRank
LIFECYCLE MANAGEMENT INTELLIGENCE ════════════════════════════════════════════════════════ REFORMULATION / LINE EXTENSION: merck.com: Keytruda SC formulation /products: SC Keytruda filing planned — new patent protection /investors: "SC conversion expected to extend franchise beyond 2036" SIGNAL: IV-to-SC switch = new formulation patents + patient preference roche.com: Perjeta + Herceptin FDC (Phesgo) /products: Fixed-dose combination capturing share from biosimilars SIGNAL: FDC strategy successfully defending against biosimilar erosion AUTHORIZED GENERIC STRATEGY: bms.com: Authorized generic Eliquis planned /investors: "AG launch timing aligned with settlement dates" SIGNAL: AG strategy to capture generic revenue — common approach INDICATION EXPANSION: novonordisk.com: Semaglutide — 6+ new indications Revenue extension: Each indication adds 2-5 years of growth SIGNAL: Indication expansion = most effective lifecycle strategy TREND: SC conversion, FDC, and indication expansion = top lifecycle tools

9Patent Strategy Benchmarking

AI agent benchmarks competitor patent strategies by analyzing filing patterns, prosecution approaches, and portfolio composition to identify strategic IP positioning advantages.

1
Benchmark IP Strategies
/legal/investors/productsOpenPageRank
PATENT STRATEGY BENCHMARKING ════════════════════════════════════════════════════════ FILING STRATEGY COMPARISON: merck.com: "Fortress" approach Avg patents per product: 85+ (maximum coverage) Focus: Method of treatment, dosing regimen, combinations Effectiveness: Highest litigation win rate (78%) novartis.com: "Platform" approach Focus: Manufacturing process, delivery technology SIGNAL: Platform patents protect multiple products simultaneously lilly.com: "Commercial" approach Focus: Fewer patents, stronger claims, lower WAC SIGNAL: Quality-over-quantity strategy reducing litigation burden PROSECUTION TRENDS: Average prosecution time: 3.2 years (increasing) Continuation applications: +18% YoY — lifecycle extension tool PCT national phase filings: Expanding to 35+ jurisdictions INNOVATION SCORE (patent novelty assessment): Most innovative portfolios: Moderna, BioNTech, Beam Therapeutics SIGNAL: Novel modality companies generating highest-value IP

10IP Intelligence Dashboard

AI agent synthesizes all patent and IP intelligence into a consolidated dashboard tracking patent cliffs, litigation outcomes, biosimilar entries, and lifecycle management activity.

1
Synthesize IP Intelligence
/investors/legal/press/productsOpenPageRank
IP INTELLIGENCE DASHBOARD — Q1 2026 ════════════════════════════════════════════════════════ PATENT CLIFF OVERVIEW: Revenue at risk (5-year): $180B across tracked products Highest exposure: Merck (Keytruda), BMS (Eliquis), Novo (GLP-1 franchise) Lifecycle strategies deployed: SC conversion, FDC, indication expansion LITIGATION STATUS: Active Hatch-Waxman cases: 142 Settlements this quarter: 6 PTAB/IPR institution rate: 68% BIOSIMILAR PIPELINE: Approved US biosimilars: 47 Interchangeable designations: 6 Average Year 1 uptake: 28% of reference volume STRATEGIC INSIGHTS: SC conversion emerging as most effective lifecycle tool Patent thicket strategy under legislative scrutiny IPR proceedings increasingly successful — patent quality critical TREND: Platform IP (LNP, ADC, degraders) becoming most valuable category

Agent Comparison Table

All ten AI agents deployed for patent and IP intelligence.

Agent NamePurposeDescriptionKey Outputs
Cliff MonitorExpiry TrackingTracks patent expiration timelines, revenue at risk, and generic entry signals from investor pagesCliff calendars, revenue impact estimates, entry timeline forecasts
Para IV TrackerGeneric ChallengeMonitors Paragraph IV filings, ANDA approvals, and Hatch-Waxman litigation outcomesChallenge alerts, filer tracking, settlement analysis
Biosimilar MonitorBiologic EntryTracks biosimilar development programs, submissions, and interchangeability designationsBiosimilar pipeline tracking, entry forecasts, erosion estimates
Portfolio AnalystIP CompetitiveAnalyzes competitor IP portfolios from filing patterns and prosecution strategiesPortfolio scorecards, filing analysis, competitive IP maps
Litigation TrackerLegal IntelTracks patent lawsuits, settlement signals, and PTAB proceedingsCase tracking, settlement forecasts, outcome analysis
Orange Book AnalystListing StrategyMonitors Orange Book listings, exclusivity grants, and patent listing strategiesOB analysis, exclusivity calendars, delisting alerts
Data Exclusivity TrackerRegulatory IPMonitors data exclusivity periods and trade secret protection strategiesExclusivity calendars, vulnerability windows, protection analysis
Lifecycle StrategistExtension IntelDetects lifecycle management activities from product pages and filing signalsLifecycle alerts, reformulation tracking, extension strategy analysis
Strategy BenchmarkerBest PracticesBenchmarks competitor patent strategies by analyzing filing patterns and portfolio compositionStrategy scorecards, benchmarks, innovation rankings
IP DashboardSynthesisAggregates all IP intelligence into executive dashboardsQuarterly IP briefs, cliff reports, litigation landscapes

Frequently Asked Questions

How does domain intelligence track patent cliff impacts?
Agents monitor investor page revenue disclosures for products approaching patent expiry, combined with legal page updates on litigation status and generic filer activity. Revenue at risk is calculated from investor-disclosed product revenue, and generic entry timelines are estimated from ANDA filing signals and settlement patterns.
Can agents detect biosimilar development programs early?
Yes. Agents monitor biosimilar developer domains for pipeline page updates, clinical trial announcements, and regulatory filing signals. Companies like Sandoz, Samsung Biologics, and Biocon disclose biosimilar development programs on their product pages well before regulatory submissions, providing 2-3 years of advance notice.
How does lifecycle management intelligence work?
Agents detect lifecycle strategies by monitoring product page updates for new formulations, press releases for reformulation filings, and investor presentations discussing franchise extension plans. Signals like SC conversion programs, fixed-dose combinations, and new indication filings are tracked as lifecycle management activities.
What patent litigation signals are available from domain analysis?
Legal pages and press releases from both innovators and generic filers reveal litigation filing, settlement negotiations, and outcome signals. Investor page disclosures about litigation provisions and authorized generic planning provide additional context for assessing litigation risk and likely resolution timelines.
How do agents benchmark competitor IP strategies?
Agents analyze patent filing volume, portfolio composition, and prosecution approach signals from legal pages and investor disclosures. Comparing patents-per-product ratios, technology focus areas, and litigation success rates enables competitive benchmarking of IP strategies across the pharmaceutical industry.

Top 10 Ways AI Agents Transform Pharmaceutical IP Intelligence

1

Patent Cliff Early Warning

Agents forecast patent cliff revenue impact years in advance by tracking expiry timelines, generic filer activity, and settlement signals across investor and legal pages.

2

Paragraph IV Challenge Detection

Automated monitoring of ANDA filings and Hatch-Waxman litigation provides early warning of generic challenges to branded products.

3

Biosimilar Pipeline Tracking

Developer domain monitoring reveals biosimilar programs 2-3 years before regulatory submissions, enabling proactive competitive response planning.

4

IP Portfolio Benchmarking

Competitive IP analysis reveals filing strategies, portfolio strengths, and prosecution approaches that inform strategic patent planning.

5

Litigation Outcome Forecasting

Settlement signal detection and historical pattern analysis improve prediction of patent litigation timelines and resolution strategies.

6

Orange Book Strategy Analysis

Patent listing monitoring reveals competitor thicket strategies and identifies potential delisting vulnerabilities that inform IP challenge planning.

7

Lifecycle Management Detection

Early detection of reformulation filings, SC conversion programs, and authorized generic plans reveals competitor lifecycle extension strategies.

8

Exclusivity Window Tracking

Automated monitoring of NCE, orphan, and pediatric exclusivity windows ensures timely awareness of competitive entry vulnerabilities.

9

Trade Secret Advantage Mapping

Manufacturing know-how and process IP analysis identifies competitive barriers beyond patent protection that affect biosimilar development feasibility.

10

Unified IP Intelligence Dashboard

Consolidated patent intelligence replaces fragmented IP monitoring with real-time tracking of cliffs, litigation, and biosimilar entries across the industry.

Get the AI Agent Database
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your Pharma AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 102M domains, 20 page types each, quarterly refreshes, and real-time change signals for pharmaceutical competitive intelligence.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.